| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | hK2; hGK-1; KLK2A2 |
| Entrez GeneID | 3817; |
| WB Predicted band size | 29kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide corresponding to residues near the C terminal of human kallikrein-related peptidase 2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于KLK2抗体的3篇示例参考文献(注：以下为虚拟示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*Development of a Monoclonal Antibody Specific for Human Kallikrein 2 (KLK2) and Its Application in Prostate Cancer Immunohistochemistry*
**作者**：Smith A, et al.
**摘要**：研究团队成功开发了一种高特异性的KLK2单克隆抗体，并通过免疫组化验证其在人类前列腺癌组织中的表达。该抗体在区分前列腺癌与良性增生中显示出高灵敏度，为病理诊断提供了新工具。
2. **文献名称**：*Targeted Inhibition of KLK2 Using Antibody-Drug Conjugates in Metastatic Prostate Cancer Models*
**作者**：Johnson B, et al.
**摘要**：本文探索了KLK2抗体偶联药物(ADC)在前列腺癌治疗中的潜力。实验表明，该抗体能特异性结合KLK2阳性肿瘤细胞，并递送细胞毒性药物，显著抑制小鼠模型中肿瘤生长和转移。
3. **文献名称**：*KLK2 as a Regulator of Androgen Signaling: Insights from Antibody-Mediated Neutralization Studies*
**作者**：Lee C, et al.
**摘要**：通过抗KLK2抗体阻断实验，研究发现KLK2可通过蛋白酶活性增强雄激素受体(AR)信号通路。抗体中和KLK2后，前列腺癌细胞增殖和侵袭能力下降，提示其作为联合治疗靶点的可能性。
---
**建议**：如需真实文献，可通过PubMed或Google Scholar搜索关键词“KLK2 antibody prostate cancer”或“KLK2 therapeutic targeting”获取最新研究。
Kallikrein-related peptidase 2 (KLK2) is a serine protease encoded by the KLK2 gene, part of the human tissue kallikrein family comprising 15 secreted enzymes. Primarily expressed in the prostate gland, KLK2 is involved in proteolytic cascades, regulating processes such as seminal clot liquefaction, cell growth, and hormone activation. Its physiological role is closely linked to prostate function, but dysregulated KLK2 expression is strongly associated with prostate cancer progression. Elevated KLK2 levels in serum or tissue are considered potential biomarkers for prostate cancer diagnosis and monitoring, often complementing prostate-specific antigen (PSA or KLK3) testing due to their structural and functional similarities.
KLK2 antibodies are immunological tools designed to detect and quantify KLK2 protein expression. These antibodies are critical in research to elucidate KLK2's biological mechanisms, its interplay with androgen receptor signaling, and its contribution to oncogenic pathways like extracellular matrix remodeling and metastasis. Clinically, KLK2-specific antibodies are utilized in immunohistochemistry (IHC) to assess prostate tumor aggressiveness and in immunoassays for biomarker validation. However, developing high-specificity antibodies remains challenging due to homology among kallikrein family members. Recent advances in monoclonal antibody engineering aim to minimize cross-reactivity, particularly with KLK3. enhancing diagnostic accuracy. Ongoing studies explore KLK2-targeting therapeutic antibodies and their utility in precision oncology, underscoring their translational relevance in prostate cancer management.
×
